The discovery that Huntington's disease results from a particular mutation of the gene for the protein dubbed "huntingtin" has created great hope that this neurodegenerative movement disorder will soon have effective treatments. Because huntingtin forms aggregates in a manner similar to amyloid-β, advances in HD research are also of particular interest to Alzheimer's researchers. In a paper published in the journal Cell, a group of researchers at Columbia University have recently demonstrated that when production of the abnormal protein is turned off, the aggregates disappear and many disease hallmarks are halted or even reversed.
The researchers made use of a particularly interesting gene system that is tetracycline-sensitive. It is, in essence, an on/off switch that can be transfected into laboratory mice and then used to turn genes off simply by adding a tetracycline analog to an animal's diet. They fused the tetracycline-sensitive genes to a gene that codes for the disease-causing huntingtin mutation. The resulting animals have huntingtin genes that are always on-constantly producing the abnormal huntingtin protein, which forms nuclear aggregates in the same pattern as in the human disease. More importantly, these mice developed the motor disturbances characteristic of Huntington's.
A subgroup of mice were fed tetracycline from the age of four months (an age at which Huntington's neuropathology and behavioral deficits are already detectable), with the effect of turning off transcription of the gene complex that includes the mutant huntingtin gene. In these animals, the aggregates of huntingtin disappeared and the motor deficits were ameliorated. Other benefits included the halting of striatal atrophy and dopamine D1 receptor loss. The important message of this result for research into other neurodegenerative diseases involving abnormal protein aggregations is that in Huntington's, constant expression of the mutant gene is necessary for a progression of the disease process. Furthermore, halting this expression can halt or even reverse the disease.—Hakon Heimer
No Available References
- Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM. Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci. 2011 May 25;31(21):7691-9. PubMed.
- Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 2000 Mar 31;101(1):57-66. PubMed.